ARDT | Ticker Profile - Titan Protect

ARDT

Ardent Health, Inc.

Healthcare · Medical Care Facilities · NYQ

$8.68

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.3B

Total market value of the company

Trailing P/E

10.00

Reasonably valued

Forward P/E

7.12

Based on estimated future earnings — lower means cheaper

Rev Growth

+7.0%

Year-over-year revenue change

Profit Margin

2.1%

How much profit the company keeps from each dollar of revenue

ROE

13.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$13.00

+50% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 11 analysts covering this stock

About Ardent Health, Inc.

Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women's services, neurology, urology, and emergency services within inpatient and ambulatory care settings. It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free-standing emergency departments, and diagnostic imaging centers. The company operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. Ardent Health, Inc. was formerly known as Ardent Health Partners, Inc. and changed its name to Ardent Health, Inc. in June 2025. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

https://www.ardenthealth.com

Country: United States Employees: 19,500 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.271

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0442

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.417

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-24.8%

Historical annualised return based on price data

Max Drawdown

-59.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

113

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$15.48

44% below the year high

52W Low

$8.07

8% above the year low

Avg Volume

388,285

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

8.7%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.94

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

132.31

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.12

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.40

Like current ratio but excludes inventory — stricter test

Gross Margin

58.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

5.1%

Profit from core operations before interest and tax

Free Cash Flow

$116M

Positive — the business generates more cash than it spends

Revenue (TTM)

$6.4B

Total revenue over the last 12 months

Net Income

$134M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$14.00

Target Median

$13.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go